PEN

Penumbra, Inc.

MedTech Long '25: Aging-Driven Procedures & Care Small Themes '25: Ghost Nations

Loading…

Overview

Aging is a big tailwind: as people age – especially with more obesity and atrial fibrillation – rates of stroke, deep-vein thrombosis, and pulmonary embolism go

Aging is a big tailwind: as people age – especially with more obesity and atrial fibrillation – rates of stroke, deep-vein thrombosis, and pulmonary embolism go up, which means more clots that may need mechanical removal. Penumbra's tools are essentially “rescue tools” for more fragile, older patients, so an older population should mean more procedures. On the flip side, an aging population also pushes payors toward cost containment and value-based care, so Penumbra must keep proving its devices shorten hospital stays and avoid complications to justify premium prices. Penumbra, Inc+2BioSpace+2

What They Do (Plain English & Analogies): Penumbra makes tools that let doctors vacuum blood clots out of blood vessels instead of relying only on drugs. Think of a tiny, smart shop-vac that goes through a straw (catheter) inside your blood vessels to suck out clots in the brain (stroke), lungs (pulmonary embolism), legs, arms, or heart. Their systems combine: (1) catheters (thin tubes), (2) a vacuum pump, and (3) in some products, computer software that turns suction on/off intelligently so more clot and less healthy blood is removed. Penumbra, Inc+3Penumbra, Inc+3PR Newswire+3
Very Brief History: Founded in 2004 in Alameda, California, focused on devices for stroke and other blood-vessel problems. Wikipedia They grew first in neuro (removing clots from brain arteries in stroke), then expanded into peripheral and coronary vessels (lungs, legs, heart). Yahoo Finance+1 They went public in 2015 and later bought control of MVI Health, a VR rehab company, and an Italian distributor (Crossmed). Wikipedia+1 In 2024 they shut down their Immersive Healthcare/VR business to refocus on core clot-removal devices. MedTech Dive+1
"Street Stereotype": On the street they're seen as a “thrombectomy pure play” – a focused med-tech name whose identity is clot removal, especially in stroke and pulmonary embolism. PR Newswire+2Penumbra, Inc+2 Stereotype: innovative, high-growth, premium-multiple med-tech that leads in aspiration-based thrombectomy, but where investors worry about one product area (clots) driving most of the story and about periodic execution / guidance swings. Investing.com+2Investors+2
Subsidiaries On Linked In*: What you can clearly see tied to Penumbra on LinkedIn and public filings includes: Penumbra, Inc. (main company); Penumbra Europe GmbH in Berlin (European operating arm); MVI Health Inc. (VR/immersive healthcare entity Penumbra owns ~90% of) NeuroNews International+3LinkedIn+3Startup Jobs+3. There are likely other local legal entities (e.g., for local sales/logistics), but those aren't consistently broken out on LinkedIn.
Customer Sectors & Example Clients: Direct customers are hospitals and health systems – especially: comprehensive stroke centers, interventional cardiology labs, vascular surgery centers, pulmonary embolism (PE) response teams, and rehab providers. LinkedIn+2PR Newswire+2 Penumbra itself states it sells via direct sales in the U.S., Europe, Canada, and Australia, and via distributors elsewhere. LinkedIn+1 Specific named institutions show up mainly via trials – e.g. Mount Sinai in New York led the STORM-PE study using Lightning Flash for PE. Investors It's reasonable to assume large academic centers and big U.S. health systems (Mayo, Cleveland Clinic, etc.) are important customers, but those are best thought of as educated guesses, not formally disclosed client lists.
New Customers / Segments They'Re Targeting: Historically, they sold mainly to specialist centers. Now they're pushing into: (1) more PE / venous thromboembolism programs, riding the STORM-PE data that suggests their device plus blood thinners beats blood thinners alone; Investors+1 (2) broader U.S. hospitals and community centers that are setting up clot-response teams; (3) Europe and other international markets as they get CE Marks for Lightning Flash 2.0 / Lightning Bolt 7 and roll out computer-assisted vacuum tech (CAVT). PR Newswire+2MedTech Dive+2 With VR shut down, they're no longer courting rehab/mental-health customers directly via REAL; those apps have been licensed out. MedTech Dive+1
How Key Themes May Help/Hurt: Main competition is any company that sells devices to treat clots in brain, lungs, legs, or heart: large med-techs like Medtronic, Stryker, Boston Scientific, Johnson & Johnson (Cerenovus), Abbott, Terumo, plus focused clot players such as Inari Medical, AngioDynamics, Merit Medical and others. Mordor Intelligence+2SkyQuest+2 Penumbra tries to be different by being: (1) aspiration-centric – think “vacuuming the clot out” vs relying mainly on stent-retrievers or clot-busting drugs; (2) a leader in computer-assisted vacuum thrombectomy (CAVT) – Lightning Flash/Bolt products that use algorithms to modulate suction and detect clot vs blood; Endovascular Today+2Penumbra, Inc+2 (3) more of a pure-play on thrombectomy than mega-conglomerates where clot devices are just one of many lines.

3 Main Long-Term Bull Details

3 Main Long-Term Bear Details

Penumbra is currently the “world's leading thrombectomy company” with strong share in multiple clot segments (stroke, venous, PE), and is still growing double-digits in thrombectomy. PR Newswire+2Penumbra, Inc+2 2) Their CAVT Lightning platform (Flash, Bolt, etc.) has clinical data (e.g., STORM-PE) suggesting better outcomes vs drugs alone, which could change treatment guidelines and expand the market. Investors+2Investors+2 3) Financially, they're showing high and rising gross margins (~66%+ with a target >70%) and solid revenue growth in the mid-teens, with U.S. thrombectomy expected to grow ~20% annually – attractive for a scaled med-tech. Investing.com+2Investing.com+2

Recent Performance & What The Market'S Focused On: 1) Concentration risk: they're heavily dependent on thrombectomy; if a competing technology, drug regimen, or safety issue reduces use of aspiration thrombectomy, a big chunk of value is at risk. MedTech Dive+1 2) Execution / cyclical med-tech risk: guidance and growth have wobbled before due to China, Europe launches, and shutting Immersive Healthcare – the stock can swing hard when guidance or margins disappoint. MedTech Dive+2Investors+2 3) Competition & pricing pressure: giants like Medtronic/Stryker/Boston Scientific plus focused players like Inari are all chasing the same procedures; payors will likely push on price if the space grows quickly, which could cap margins longer-term. Mordor Intelligence+2SkyQuest+2

Bull / Bear Details

Penumbra is a focused “clot-removal and vessel-care” med-tech company. The updated thesis is that Level 1 PE data (STORM-PE), accelerating embolization growth,

Thesis

Penumbra is a focused “clot-removal and vessel-care” med-tech company. The updated thesis is that Level 1 PE data (STORM-PE), accelerating embolization growth, and a deep CAVT pipeline (Flash/Bolt, Thunderbolt) support a multi-year high-teens revenue and faster margin expansion story, but this is balanced against premium valuation and concentrated exposure to one treatment paradigm (thrombectomy).

Bull case

CAVT (computer-assisted vacuum thrombectomy) has strong clinical and economic data in PE and VTE, with STORM-PE likely to drive more protocols and guidelines toward mechanical clot removal, expanding procedure volume and Penumbra's share for many years.
The new 50+ person embolization sales force and Ruby XL launch show the non-thrombectomy portfolio can grow >20% YoY, making the model less dependent on a single franchise while still benefiting from aging, clot-prone populations.
Margin structure is moving toward “top-tier med-tech”: gross margin already near 68% with a credible path to 70%+ and rising operating margins, supported by mix (more U.S./CAVT), scale, and improved manufacturing, giving significant long-term EPS power.

Bear case

Business is highly concentrated in thrombectomy; if alternative drugs, competing devices, or safety concerns reduce the perceived need for mechanical clot removal, growth and valuation could both compress sharply.
Competition from large med-tech players and focused thrombectomy companies may pressure pricing, limit share gains, or force higher commercial spend, reducing the margin upside investors are baking in today.
Valuation remains rich versus med-tech peers; any disappointment in STORM-PE adoption, slower-than-hoped Thunderbolt approval/launch, or a stumble in international growth/margins could trigger a meaningful de-rating even if the long-term story remains intact.

Bull / Bear Case

Bear Case: Shares trade at a rich valuation (forward P/E ~60x and P/S ~8.5–9x), leaving little room for error if growth slows. The business is concentrated in thrombectomy and faces intense competition from large med-techs and focused clot players. Any stumble in STORM-PE adoption, Thunderbolt approval/launch, or margins (tariffs, mix, pricing) could trigger a sharp multiple de-rating. Webull+3Fidelity International+3StockStory+3
Bull Case: Penumbra is the leading “vacuum clot-removal” player with strong positions in stroke, DVT and PE. STORM-PE provides rare Level 1 data that can expand PE/VTE procedures for years, while CAVT upgrades (Flash/Bolt, Thunderbolt) plus a now-scaled embolization sales force and margin expansion toward ~70% support a multi-year high-teens revenue and faster earnings growth story. Simply Wall St+1
More Compelling & Why: Slight edge to the bull case, but not a “table-pounding cheap” situation. At ~$295, the stock embeds high expectations with only modest upside to many fair-value estimates, yet the combo of underpenetrated PE/DVT market, strong clinical data, clear product roadmap, and margin runway still makes the long-term risk/reward reasonably attractive for growth-oriented investors who can tolerate volatility. Fidelity International+2Simply Wall St+2

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Evidence of STORM-PE driving PE/VTE procedure growth	The core bull case is that Level 1 STORM-PE data materially increases use of CAVT in pulmonary embolism and venous disease (VTE). Early signs that hospitals are changing protocols and volumes are ramping are key.	Qualitative: management commentary, hospital protocol changes, PER/PERT consortium updates. Quantitative: any hints intraquarter about U.S. VTE growth being stronger than “mid-30s%” or new accounts coming online.	Bullish: Mgmt talks about meaningfully higher PE/VTE case growth vs prior trend, more hospitals adding programs, or protocol updates at major systems. Bearish: Mgmt suggests slower-than-expected protocol change, or emphasizes “long education cycle” without offsetting volume anecdotes.	Listen to any fireside chats/healthcare conferences; read KOL commentary from TCT/VIVA/other PE meetings; watch for company press releases about PE/VTE milestones or society guideline work.	Google Trends for “pulmonary embolism thrombectomy,” “PE response team,” “Lightning Flash procedure”; monitoring PERT Consortium updates or conference agendas.	Hospital procedure-level datasets (where available), PE/VTE ICD/procedure tracking vendors; sell-side channel checks; claims-based panels that tag thrombectomy for PE/DVT.
Embolization & Access momentum (coils, Ruby XL, Swift, MMA use)	Q3 showed a big step-up in embolization & access growth (>20% YoY). The debate is whether this is a sustainable second growth pillar or a post-launch blip.	Intraquarter commentary on the new 50+ rep embolization team: are they “ahead of plan” or “still ramping”? Any comments on MMA embolization uptake and Ruby XL order trends.	Bullish: Mgmt calls the embolization performance “sustainable,” highlights continued strong sequential growth and deeper MMA adoption, and doesn't frame Q3 as unusually “loaded.” Bearish: They describe Q3 as having pent-up demand, channel fill, or say that growth will normalize down meaningfully.	Track management comments at peripheral and neuro embolization-focused meetings; read any press/abstracts touting Penumbra's coils in MMA or other embolization indications.	PubMed and conference abstracts for embolization/MMA using Penumbra coils; Google Trends for “middle meningeal artery embolization” and “Ruby coil” searches.	Cath lab procedure datasets for embolization; coil market trackers; survey-based reports on MMA embolization adoption and vendor share.
Thunderbolt FDA decision / regulatory update	Thunderbolt (neuro CAVT for stroke) is a major new leg to the story. Approval and launch timing drive how quickly Penumbra can re-accelerate stroke growth and extend its CAVT “moat” into the brain.	Any 8-K, press release, or management comment about Thunderbolt 510(k) clearance, additional data requests, or delays.	Bullish: 510(k) clearance announced; clear launch time line within a quarter and confident commentary → suggests new stroke growth leg. Bearish: Noticeable delay (e.g., explicit “pushed beyond year-end/first-half” or request for extra clinical data) → undermines near-term growth and “innovation catalyst” narrative.	Track company press releases and SEC 8-Ks; scan earnings call transcripts and major conferences (e.g., neuro/interventional meetings) for Thunderbolt mentions. Company IR page and financial news terminals will flag any clearance headline quickly.	Google News alerts for “Penumbra Thunderbolt approval” and “CAVT neuro thrombectomy”; Twitter/Reddit searches around big stroke meetings for doc chatter.	FDA device approval feeds; broker research; real-time news (Bloomberg/FactSet/Refinitiv); specialist med-tech newsletters.
Gross margin / cost or pricing surprises	The path toward >70% gross margin and expanding operating margin is central to the valuation. Negative news on costs, pricing, tariffs, or product mix could be an early sell signal; positive signals strengthen the bull case.	Any indication of unexpected cost pressure (materials, labor, tariffs) or pricing pushback from payors/hospitals; commentary that mix is shifting away from high-margin CAVT or that Ruby XL cost issues have resurfaced.	Bullish: Mgmt reiterates confidence in 70%+ GM by end of 2026 and talks about additional tailwinds (e.g., higher CAVT mix, productivity gains) with no new headwinds. Bearish: New comments about margin pressure from tariffs/pricing, supply issues, or needing to invest more heavily in sales/market access than planned.	Earnings call next quarter will give the official number, but intraquarter you can watch for any pre-announcements, conferences where margin is discussed, or regulatory/tariff changes that hit med-tech imports.	Government tariff announcements; industry blogs on med-tech reimbursement and pricing; Google News alerts for “Penumbra pricing,” “Penumbra tariff,” “thrombectomy reimbursement.”	Reimbursement/ASP tracking products, cost-inflation dashboards (freight, materials) from data vendors, and broker models that update intraquarter on margin expectations.
U.S. Thrombectomy growth commentary vs 20–21% target	U.S. thrombectomy is the main revenue engine. Mgmt reiterated 20–21% growth for 2025; confidence or wavering around that target will move the stock even before the next print.	Any intraquarter update at conferences/IR days: do they reaffirm, talk about “tracking ahead of plan,” or hint at “lumpiness,” especially in stroke vs VTE/arterial?	Bullish: Explicit or implied language that U.S. thrombectomy is trending at or above the 20–21% full-year range (or that VTE/arterial strength more than offsets stroke softness). Bearish: Hints that stroke weakness is persisting and offset is getting harder, or they downplay ability to sustain high-teens/20% growth.	Watch management remarks at upcoming med-tech conferences, non-deal roadshows, and any mid-quarter business updates; transcripts typically posted on IR site and financial data services.	Social-media / doc forums (e.g., speciality LinkedIn posts) mentioning Lightning/Indigo usage; Google Trends for “catheter thrombectomy” and “Penumbra Lightning.”	Claims-based growth trackers for thrombectomy procedures, cardiology/interventional panel data, and sell-side “doc survey” products focused on PE/DVT/stroke device use.

Key Reported Metrics3 rows

Metric	Why It Matters	Last Period
Gross Margin % Trend	GM expansion is one of the biggest drivers of long-term valuation. If mix shifts toward U.S. and CAVT, margins should keep climbing toward the 70% target. Any reversal (manufacturing, tariffs, product mix) would be a red flag.	67.8% GM (+130 bps YoY) (Q3 2025)
Embolization & Access Revenue Growth	The new 50+ rep embolization sales force just delivered a breakout quarter. The question: was Q3 the “reset level” or an anomaly? Continued >20% YoY growth indicates durable penetration and strong momentum in MMA embolization and coils.	'+22.0% YoY (Q3 2025)
U.S. Thrombectomy Revenue Growth	This is Penumbra's core engine. Adoption of CAVT devices (Flash/Bolt) plus early impact from STORM-PE should show up here first. Sustained high-teens/20%+ growth would confirm increasing share gains and more PE/DVT cases.	'+18.5% YoY (Q3 2025)

Rerating Thresholds3 rows

Metric	What'S Needed For Rerating	Why It Matters	Earnings Date
Gross Margin % Trend	For the stock to rerate higher, Penumbra needs to report a Q1 2026 gross margin of at least 69%, demonstrating accelerated progress towards its stated goal of achieving 70%+ gross margin by the end of 2026. This would represent a significant sequential improvement from the 68.0% reported in Q4 2025 and would be further bolstered by strong management commentary on sustainable drivers of margin expansion, such as favorable product mix (U.S./CAVT) and manufacturing efficiencies.	Achieving a gross margin of 69% or higher, and accelerating towards the 70%+ target, is crucial as gross margin expansion is a primary driver of Penumbra's long-term valuation and EPS power. It validates the company's path to a 'top-tier med-tech' margin structure, confirming the investment thesis that mix shifts and improved manufacturing are yielding significant profitability gains and strengthening its competitive position.	2026-04-29
Embolization & Access Revenue Growth	For Penumbra's stock to rerate higher, Embolization & Access Revenue Growth for Q1 2026 would need to hit 25% YoY or higher. This would significantly exceed the implied 'weak' Q1 results that recently caused the stock to sink and demonstrate sustained robust momentum, building on the +22.0% YoY seen in Q3 2025 and the accelerated +37.0% YoY in Q4 2025.	Hitting this threshold matters because sustained strong growth in Embolization & Access validates Penumbra's diversification strategy beyond thrombectomy, signaling successful execution of its new sales force and product launches. It would counter recent market concerns about slowing growth in this segment, reinforcing the long-term investment thesis and potentially driving a positive rerating amidst the proposed acquisition and lack of forward guidance.	2026-04-29
U.S. Thrombectomy Revenue Growth	U.S. Thrombectomy Revenue Growth needs to re-accelerate significantly from the Q4 2025 reported value of +12.4% YoY. For the stock to rerate higher, it would need to hit or exceed the company's previously stated target range of 20-21% YoY, demonstrating a strong rebound and validating the core investment thesis amidst recent operational setbacks and negative sentiment.	This metric is Penumbra's core growth engine, confirming increasing market share and procedure volume for its clot-removal devices. Exceeding 20% growth would validate the computer-assisted vacuum thrombectomy (CAVT) thesis, justify its premium valuation, and mitigate concerns about business concentration and recent operational setbacks.	2026-04-29

Earnings Transcript SummaryTable

2025-12-01 · 2025 Q3 Earnings

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
1) Driving adoption of CAVT “vacuum” tech for clots (VTE/PE + arterial + stroke). They emphasized computer-assisted vacuum thrombectomy (CAVT) devices like Lightning Flash/Bolt (for clots in lungs/veins/arteries) and upcoming Thunderbolt (for brain/stroke). The big goal is to treat a much larger share of ~800k U.S. venous + arterial clot patients and keep shifting doctors from older tools and drugs to CAVT. Webull+1 2) Turning STORM-PE trial into real-world PE procedure growth. Management is laser-focused on using the strong PE trial (STORM-PE) to change hospital protocols so more pulmonary embolism patients get mechanical clot removal, not just blood thinners. They talked about working with societies, PER/PERT teams, and non-interventional specialists (pulmonologists, hematologists) to update protocols over the next year. Webull+1 3) Margin expansion while scaling embolization. They highlighted gross margin moving to 67.8% (up 130 bps YoY) and reiterated the goal of >70% gross margin by end of 2026, plus operating margin expanding even faster. A big focus is stabilizing Ruby XL manufacturing, leveraging the new 50+ person embolization sales team, and keeping tariffs from dinging margins. Webull+2PR Newswire+2	Overall takeaway: This was a strong, upbeat call with a “confident but not crazy” tone. Penumbra is firing on multiple cylinders: U.S. thrombectomy (especially clots in veins and lungs) and embolization both grew strongly, international finally returned to growth, margins moved up nicely, and they raised full-year revenue guidance to $1.375–1.38B while reiterating 20–21% U.S. thrombectomy growth. Webull+1 The story the call tells for a generalist: (1) Clot-removal “vacuum” tools keep gaining share vs older tools/drugs, especially for clots in lungs/veins (VTE/PE); (2) new clinical data (STORM-PE) plus better hardware/software (Flash 3.0, Bolt expansions) should pull more hospitals and doctors into using Penumbra systems; (3) they are managing the “plumbing” of the business well — new embolization sales force is working, Ruby XL manufacturing is fixed, China headwinds are fading, and margins are moving toward 70%. Management sounded confident, data-driven, and long-term focused, while staying cautious on giving specifics about Thunderbolt timing.	Total revenue: +13.4% YoY to $339.5M (slower than Q3's +17.8%). Global thrombectomy: +13.1% YoY to $230.3M (accelerated to +15.8% in Q3). Embolization & access: +13.9% YoY to $109.2M (accelerated sharply to +22.0% in Q3). U.S. revenue: +19.5% YoY (vs +21.5% in Q3). International revenue: –3.2% YoY (returned to +6.6% growth in Q3 as China drag eased). PR Newswire+2TradingView+2	1) Thunderbolt timing, FDA process, and stroke growth. Multiple analysts pressed about when Thunderbolt (brain CAVT device) might be approved and how big it could be. Mgmt's response: this is a new device (not just a new “use” for an old one), so the neuro division's 510(k) reviews take time but are tracking similarly to prior products; they've already answered all major FDA questions, now in the “final clarifications” phase. They stayed optimistic but refused to give an exact approval date; they said they're fully ready to launch once cleared. Webull 2) STORM-PE impact on procedure volume and adoption curve. Analysts asked if STORM-PE is enough to change practice and pull in new hospitals and smaller centers. Mgmt said reaction from both interventional and non-interventional doctors has been “uniformly positive”; non-procedural doctors are already pushing to change hospital protocols, and they've seen immediate interest and case uptake from doctors who previously didn't use Flash. They expect protocols to change first, with society guidelines following and PE + DVT volumes building into 2026. Webull 3) Growth durability, especially thrombectomy vs embolization, and margins. Questions centered on (a) whether U.S. thrombectomy growth is slowing and what happens in stroke; (b) whether embolization's big Q3 jump is sustainable; (c) how margins trend, including tariff impact. Mgmt said: U.S. thrombectomy is still mid-teens+ with VTE leading and arterial strong; stroke has been softer but Penumbra is taking share and expects “waves” of growth with new tech like Thunderbolt. Embo & access growth is not a one-time spike — the new dedicated sales team plus procedures like MMA embolization should support durable growth. On margins, Q3 already reflects tariff headwinds; they still see sequential GM improvement from mix (more U.S., more CAVT) and productivity, with leverage in SG&A now that the embolization build-out is largely complete. Webull+2Stock Insights+2	Total revenue: +17.8% YoY to $354.7M. Global thrombectomy (clot-removal devices): +15.8% YoY to $236.4M. Embolization & access (coils + access tools): +22.0% YoY to $118.3M. U.S. revenue: +21.5% YoY to $275M. International revenue: +6.6% YoY to $79.7M (about +3% in constant currency). Webull+1

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	IS CHANGE	Price Reaction
2025-11-05	Penumbra delivered a strong Q3 with high-teens revenue growth, accelerating thrombectomy and standout embolization/access driven by Ruby XL and a new dedicated sales force. STORM-PE data drew very positive physician reaction, likely expanding PE/VTE procedures and share. Margins improved toward a 70% gross margin goal, China drag is fading, and Thunderbolt for stroke is a key upcoming catalyst.	Earnings Transcript	Bullish			+18.02% (vs SPY: +17.45%)